Clinical characteristics of cerebral venous sinus thrombosis

Jia-Wei Wang, MD, PhD, Jin-Ping Li, MD, PhD, Ying-Lun Song, MD, MS, Ke Tan, MD, PhD, Yu Wang, MD, BS, Tao Li, MD, MS, Peng Guo, MD, MS, Xiong Li, MD, PhD, Yan Wang, MD, MS, Qi-Huang Zhao, MD, PhD.

ABSTRACT

Objectives: To investigate the risk factors, clinical presentation, neuroimaging features, treatment, and prognosis of patients with cerebral venous sinus thrombosis (CVST).

Methods: We retrospectively analyzed the data of 19 patients with a diagnosis of CVST admitted to Beijing Chao-Yang Hospital affiliated to Capital Medical University, Beijing, China between January 2010 and December 2013.

Results: There were 9 men and 10 women (age range: 27-75 years). Headache (84.2%) and focal signs (57.9%) were the 2 most common symptoms. Direct evidence of thrombosis was found on CT in 42.1%, and on MRI in 52.6%. Two or more sinuses were involved in 78.9% of cases, in which the transverse sinus plus sigmoid sinus were the most commonly involved combination. All patients received anticoagulant therapy. Most patients (84.2%) had no neurological sequelae at discharge, and only 3 patients (15.8%) recovered with sequelae.

Conclusion: Our study provides detailed information on the clinical manifestations, neuroimages, management, outcome, and risk factors of the patients with CVST.

Disclosure. The authors have no affiliation or financial involvement with organizations or entities with a direct financial interest in the subject matter or materials discussed in the manuscript. No funding was received for this work from any organization.
other 8 cases. There were focal motor or sensitive deficits in the remaining 3 patients without headache. In the clinical course, 3 patients demonstrated worsening of the presenting symptoms, and one patient developed additional symptoms. The models of onset of symptoms were also highly variable. It was acute (<48 hours) in 8 patients (42.1%), sub-acute (≥48 hours, <1 month) in 9 patients (47.4%), and chronic (≥1 month) in the remaining 2 patients (10.5%).

Cranial CT and MRI scans were performed in all the 19 patients. The CT scan in 8 patients (42.1%) revealed signs suggestive of CVST (empty delta sign, dense sinus sign, or cord sign) while the MRI scan in 10 patients (52.6%) showed signs of CVST (the combination of absence of a flow void with alteration of signal intensity in the dural sinus). Table 1 summarizes the neuroimaging characteristics of the parenchymal lesions on CT/MRI scan in 19 patients with CVST. An MRV scan was performed in 11 cases, and a DSA scan was performed in 8 cases. The results of the MRV and DSA scans demonstrated the involvement of different sinuses and veins in the patients with CVST (Table 2). The superior sagittal sinus was involved in 10 patients (52.6%), while the transverse sinus was involved in 16 (84.2%) patients, and the sigmoid sinus in 14 (73.7%) patients.

Table 1 - Presenting symptoms/signs and parenchymal lesions on CT/MRI scan in 19 patients with CVST.

| Variable                          | n   | (%) |
|-----------------------------------|-----|-----|
| Symptoms/signs                    |     |     |
| Headache                          | 16  | (84.2) |
| Seizures                          | 6   | (31.6) |
| Generalized                       | 2   | (10.5) |
| Focal                             | 4   | (21.1) |
| **Focal deficits**                |     |     |
| Motor                             | 10  | (52.6) |
| Sensitive                         | 1   | (5.3) |
| Altered consciousness             | 1   | (5.3) |

| Parenchymal lesions on CT/MRI scan |     |     |
|-----------------------------------|-----|-----|
| Normal                            | 6   | (31.6) |
| Non-hemorrhagic venous infarct    | 6   | (31.6) |
| Hemorrhagic venous infarct        | 5   | (26.3) |
| Intracerebral hemorrhage          | 2   | (10.5) |

**CVST** - cerebral venous sinus thrombosis

Table 2 - Sites of involvement in 19 patients with CVST.

| Variable                              | n |
|---------------------------------------|---|
| **One site**                          |   |
| Superior sagittal sinus               | 2 |
| Transverse                           | 1 |
| Sigmoid                              | 1 |
| **Two sites**                         |   |
| Superior sagittal + transverse        | 1 |
| Transverse + sigmoid                  | 7 |
| **Three or more sites**               |   |
| Superior sagittal + transverse + straight + sigmoid | 1 |
| Superior sagittal + transverse + deep veins | 1 |
| Superior sagittal + transverse + sigmoid | 5 |
| **Total**                             | 19 |

**CVST** - cerebral venous sinus thrombosis

Table 3 - Risk factors in 19 patients with CVST.

| Risk factors                  | n |
|------------------------------|---|
| Unknown                      | 2 |
| **Thrombophilia**            |   |
| Hyperhomocysteinemia         | 4 |
| Protein C deficiency         | 1 |
| Protein S deficiency         | 3 |
| **Systemic disorders**       | 4 |
| Systemic lupus erythematosus | 1 |
| Thyroid disease              | 1 |
| Kidney transplantation       | 1 |
| Hepatic dysfunction          | 1 |
| Tumor*                       | 2 |
| **Infection**                | 9 |
| Central nervous system       | 1 |
| Ear, sinus, mouth, face, and neck | 8 |
| Puerperium                   | 2 |
| **Drugs**                    | 3 |
| Oral contraceptives          | 1 |
| Immunosuppressor             | 2 |

*Includes 2 gastrointestinal carcinomas

**CVST** - cerebral venous sinus thrombosis
As far as treatment was concerned, most patients (12 cases, 63.2%) were anti-coagulated with subcutaneous low-molecular-weight heparin (LMWH) in therapeutic dosages followed by oral anticoagulants. A few patients received only subcutaneous LMWH in prophylactic dosage (6 cases, 31.6%) or oral anticoagulants (one case, 5.2%). During the treatment, subcutaneous LMWH treatment in prophylactic dosage was stopped in 2 patients developing significant expansion of the initial hematoma. One patient who demonstrated significant worsening of neurological function following treatment with subcutaneous LMWH in therapeutic dosages was treated with endovascular mechanical thrombectomy after repeated MRI indicated the fresh venous infarction. Additional treatments included antiepileptic drugs (6 cases, 31.6%) and osmotherapy (7 cases, 36.8%). Risk factors are listed in Table 3. Most patients (16 cases, 84.2%) had no neurological sequelae and were symptom-free at the time of discharge. Three of the patients (15.8%) recovered with sequelae.

**Discussion.** As shown in our study, headache was the most common symptom, and present in 84.2% of patients with CVST, which is consistent with the data from the International Study on Cerebral Venous and Dural Sinuses Thrombosis. Generally, headache is indicative of intracranial hypertension resulting from impaired venous drainage in the patients with CVST. In addition to increased intracranial pressure, another important pathological mechanism in CVST is focal brain injury attributable to venous infarction or hemorrhage, which can lead to focal neurological deficits or seizure. Neurological signs and symptoms in patients with CVST are commonly related to the affected brain regions. Previous research has indicated headache may occur either alone or in combination with focal deficits. Isolated headache without focal neurological deficits occurred in 8 patients (42.1%) in our study, which often presents a significant diagnostic challenge and delay in treatment in the clinical practice. In addition, one patient in our series showed altered level of consciousness due to involvement with the deep venous drainage system, and bilateral involvement of deep venous system has been indicated as a diagnostic clue for CVST.

Apart from the clinical presentation, the current diagnosis of CVST is mainly based on the neuroradiological findings. Empty delta sign, dense sinus sign, or cord signs on CT image and the combination of absence of a flow void with alteration of signal intensity in the dural sinus on MRI image are the suggestive signs of CVST. The 2 most frequent sites of thrombosis in our study were the transverse (84.2%) and the sigmoid sinus (73.7%), which is compatible with previous reports. Another remarkable feature of CVST is that thrombosis often affects several sinuses, and 78.9% of cases (15 out of 19 patients) in our study showed involvement of 2 or more sinuses. According to previous research, thrombosis in the transverse and sigmoid sinus has been strongly associated with the incidence of local infection such as otitis media, which was present in 8 (42.1%) patients in the present study.

Evidence is emerging that initial anticoagulant therapy in CVST is beneficial in preventing thrombus growth and venous thromboembolism, facilitating recanalization, and improving outcome in patients with CVST. However, there are controversies regarding the administration route and dosage of the anticoagulants because venous infarction with hemorrhagic transformation or intracranial hemorrhage (ICH) is commonly present in the course of CVST. All patients with CVST in our study received anticoagulant therapy. Previous randomized controlled trials demonstrated that anticoagulation with LMWH did not increase the risk of cerebral bleeding, even in patients with cerebral hemorrhage. Data from observational studies indicated a range of risks for ICH after anticoagulation for CVST from 0 to 5.4%. There is a lack of evidence supporting hemorrhage enlargement or that fresh hemorrhage is associated with treatment with anticoagulant therapy, which is compatible with our results indicating that hemorrhage enlargement occurred in patients with LMWH treatment in a prophylactic dosage instead of in a therapeutic dosages.

In the present study, one patient (5.3%) developed significantly poorer neurological function. The reasons leading to a poorer clinical condition during LMWH treatment in therapeutic dosages may be persistent thrombosis, which is supported by the repeated MRI scan showing fresh venous infarction. In recent years, there are increasing case reports and small case series showing that endovascular mechanical thrombectomy is beneficial for the patients with clinical deterioration despite use of anticoagulation or uncontrolled intracranial hypertension resistant to standard therapy. Continued research is essential to better understand the role of aggressive intervention such as mechanical thrombectomy in the treatment of CVST.

Our data indicated there were 2 or more risk factors in 47.3% of patients with CVST, which is consistent with previous reports. Therefore, the identification of
one risk factor should not stop the search for additional risk factors, in particular inherited or acquired thrombophilia. It is notable that the laboratory examination for inherited thrombophilia such as factor V Leiden positivity and prothrombin G20210A mutation is not carried out in our hospital, which is a limitation of the present study. Previous study has demonstrated that coma, cerebral hemorrhage, and malignancy are the important prognostic factors for death or dependence, which agrees with our findings of cerebral hemorrhage in the 3 patients with neurological sequelae at discharge in our series. These findings remind us that we should pay close attention to the patients with poor prognostic factors.

In conclusion, our study provided details on the clinical manifestations, neuroradiological findings, management, outcome, and risk factors of the patients with CVST in our hospital.

Received 12th October 2014. Accepted 18th May 2015.

From the Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China. Address correspondence and reprint request to: Dr. Qi-Huang Zhao, Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, 8 South Gongti Road, Beijing 100020, P. R. China. E-mail: chaoyanghospital@126.com

References

1. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2011; 42: 1158-1192.

2. Einhaupl K, Stam J, Bousser MG, De Bruijn SF, Ferro JM, Martinelli I, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. *Eur J Neuro* 2010; 17: 1229-1235.

3. Viegas LD, Stolz E, Canhao P, Ferro JM. Systemic thrombolysis for cerebral venous and dural sinus thrombosis: a systematic review. *Cerebrovasc Dis* 2014; 37: 43-50.

4. Gulati D, Strbian D, Sundararajan S. Cerebral venous thrombosis: diagnosis and management. *Stroke* 2014; 45: e16-e18.

5. Meckel S, Reisinger C, BREMERICH J, DAMM D, WOLBERS M, ENGELSER S, et al. Cerebral venous thrombosis: diagnostic accuracy of combined, dynamic and static, contrast-enhanced 4D MR venography. *AJNR Am J Neuroradiol* 2010; 31: 527-535.

6. Damak M, Crassard I, Wolff V, Bousser MG. Isolated lateral sinus thrombosis: a series of 62 patients. *Stroke* 2009; 40: 476-481.

7. Miranda B, Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, et al. Venous thromboembolic events after cerebral vein thrombosis. *Stroke* 2010; 41: 1901-1906.

8. Davie CA. Anticoagulation in cerebral venous sinus thrombosis. *Eur J Neurol* 2012; 19: 933-934.

9. Uzar E, Ekici F, Acar A, Yucel Y, Bakir S, Tekbas G, et al. Cerebral venous sinus thrombosis: an analyses of 47 patients. *Eur Rev Med Pharmacol Sci* 2011; 16: 1499-1505.

10. Nelson S, Ho B. Extensive cerebral venous thrombosis. *JAMA Neurol* 2013; 70: 1070-1071.

11. Dashti SR, Hu YC, Yao T, Fiorella D, Mitha AP, Albuquerque FC, et al. Mechanical thrombectomy as first-line treatment for venous sinus thrombosis: technical considerations and preliminary results using the Angiojet device. *J Neurointerv Surg* 2013; 5: 49-53.

12. Nimjee SM, Powers CJ, Kolls BJ, Smith T, Britz GW, Zomorodi AR. Endovascular treatment of venous sinus thrombosis: a case report and review of the literature. *J Neurointerv Surg* 2011; 3: 30-33.

13. Nasr DM, Brinjikji W, Cloft HJ, Saposnik G, Rabinstein AA. Mortality in cerebral venous thrombosis: results from the national inpatient sample database. *Cerebrovasc Dis* 2013; 35: 40-44.